TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?
Weill's acquisition increased his direct holdings to 16,392 shares, valued at $1.4 million at recent market prices, amid a 30% decline in the stock over the past year.
Overview
David Weill, a Director at TransMedics Group, Inc. (NASDAQ:TMDX), purchased 1,336 shares of common stock on Sept. 11, 2026. SEC Form 4 filing
Transaction value based on SEC Form 4 weighted average purchase price ($81.63); post-transaction value based on Sept. 11, 2026, market close ($82.18).
Details
TransMedics Group is a commercial-stage medical technology enterprise with a market capitalization of $2.7 billion and TTM revenues of $668.5 million, demonstrating significant scale in the organ transplantation technology sector. The company's Organ Care System represents a differentiated approach to donor organ preservation, using proprietary perfusion technology to recreate near-physiological conditions and extend the viability window of organs. This innovation positions TransMedics as a critical enabler of expanded criteria donor utilization and improved transplant outcomes, providing a competitive advantage in addressing the substantial global shortage of viable donor organs.
Source
Originally published at www.fool.com.